---
document_datetime: 2023-09-21 18:27:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/celvapan-epar-all-authorised-presentations_en.pdf
document_name: celvapan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.714467
conversion_datetime: 2025-12-22 22:32:03.05292
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EU Number

EU/1/08/506/001

Invented name

Celvapan

Strength

7.5

microgram

/0.5 ml

1

Whole virion influenza vaccine, inactivated containing antigen of pandemic strain*:

1 A/California/7/2009 (H1N1)v 7.5 micrograms** per 0.5 ml dose

* propagated in Vero cells (continuous cell line of mammalian origin)

** expressed in micrograms haemagglutinin.

Pharmaceutical

Form

Suspension for injection

Route of

Administration

Intramuscular use

Packaging vial (glass)

Content (concentration)

0.5 ml

1/1 Medicinal product no longer authorised

Package size

20 vials